Orthofix Medical Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Orthofix Medical Inc. filed its Q1 2024 10-Q, detailing acquisitions and financial reporting.</b>

AI Summary

Orthofix Medical Inc. (OFIX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Orthofix Medical Inc. filed a 10-Q report for the period ending March 31, 2024. The filing references the acquisition of SeaSpine Holdings Corporation on January 5, 2023. It also mentions the NeoMedical acquisition and related preferred stock and convertible loan agreements. Fair value measurements, including Level 3 inputs for Lattus Spine, are detailed for March 31, 2024. The company's business address is 3451 Plano Parkway, Lewisville, TX 75056.

Why It Matters

For investors and stakeholders tracking Orthofix Medical Inc., this filing contains several important signals. The 10-Q filing provides updated financial statements and disclosures for the first quarter of 2024, crucial for investors to assess the company's performance and financial health post-acquisitions. Details on fair value measurements and specific financial instruments like convertible loan agreements offer insights into the company's valuation strategies and potential financial risks or opportunities.

Risk Assessment

Risk Level: medium — Orthofix Medical Inc. shows moderate risk based on this filing. The filing contains numerous references to specific financial instruments, acquisitions (SeaSpine, NeoMedical), and fair value measurements, indicating a complex financial structure and potential for detailed scrutiny regarding valuation and integration.

Analyst Insight

Investors should review the detailed financial statements and notes within the 10-Q to understand the impact of recent acquisitions and fair value accounting on Orthofix Medical's financial position.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2024-05-07 — Filing Date (10-Q filing)
• 2023-01-05 — SeaSpine Acquisition Date (Mentioned in filing)

Key Players & Entities

• Orthofix Medical Inc. (company) — Filer
• SeaSpine Holdings Corporation (company) — Acquisition reference
• NeoMedical (company) — Acquisition reference
• BlueTorch Finance LLC (company) — Financing agreement reference
• Lewisville, TX (location) — Business address

FAQ

Risk Factors

• Fair Value Measurements [medium — financial]: The company details fair value measurements, including Level 3 inputs for Lattus Spine, for recurring fair value measurements as of March 31, 2024.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q
• 2024-05-07: Filing Date — Date the 10-Q was officially submitted to the SEC
• 2023-01-05: SeaSpine Acquisition — Key event referenced in the filing

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides an update on the company's financial performance and condition during the quarter.)

Fair Value Measurements

The process of determining the price at which an asset would be sold or a liability would be transferred in an arm's length transaction. (Crucial for valuing assets and liabilities, especially in acquisitions and for financial instruments.)

Key Financial Figures

• $0.10 — nge on which registered Common stock, $0.10 par value per share OFIX Nasdaq Glo

Filing Documents

• ofix-20240331.htm (10-Q) — 1887KB
• ofix-ex10_13.htm (EX-10.13) — 34KB
• ofix-ex10_18.htm (EX-10.18) — 166KB
• ofix-ex10_19.htm (EX-10.19) — 34KB
• ofix-ex10_25.htm (EX-10.25) — 173KB
• ofix-ex10_26.htm (EX-10.26) — 119KB
• ofix-ex31_1.htm (EX-31.1) — 13KB
• ofix-ex31_2.htm (EX-31.2) — 13KB
• ofix-ex32_1.htm (EX-32.1) — 11KB
• img187969499_0.jpg (GRAPHIC) — 2KB
• img193510625_0.jpg (GRAPHIC) — 2KB
• img222633288_0.jpg (GRAPHIC) — 3KB
• 0000950170-24-053966.txt (&nbsp;) — 9748KB
• ofix-20240331.xsd (EX-101.SCH) — 1504KB
• ofix-20240331_htm.xml (XML) — 1721KB

Financial Statements

Financial Statements 4 Condensed Consolidated Balance Sheets as of March 31, 2024, and December 31, 2023 4 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024, and 2023 5 Condensed Consolidated Statements of Changes in Shareholders' Equity for the three months ended March 31, 2024, and 2023 6 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024, and 2023 7 Notes to the Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 32

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended ("the Exchange Act"), and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts, and projections. All statements, other than statements of historical fact, contained in this report, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "projects," "intends," "predicts," "potential," or "continue" or the negative version of those terms and other similar expressions. Forward-looking statements include, but are not limited to, statements about: our future operations, sales, expenses, and financial performance; our operating results; our intentions, beliefs, and expectations regarding the anticipated benefits of the merger with SeaSpine Holdings Corporation ("SeaSpine"), including the anticipated synergies and cost-savings from the merger; our plans for future products and enhancements of existing products; anticipated growth and trends in our business; the timing of and our ability to maintain and obtain regulatory clearances or approvals; our belief that our cash and cash equivalents, investments, and access to our credit facilities will be sufficient to satisfy our anticipated cash requirements; our relationships with customers and distributors; our manufacturing abilities and the performance of our suppliers; our ability to achieve market penetration and the success of our expansion efforts; anticipated trends and challenges in the markets in which we operate; and the impact of investigations, claims, and litigation. Forward-looking statements are not guarantees of future performance and involve risks

F INANCIAL INFORMATION

PART I. F INANCIAL INFORMATION I tem 1. Financial Statements ORTHOFIX MEDICAL INC. C ondensed Consolidated Balance Sheets (U.S. Dollars, in thousands, except par value data) March 31, 2024 December 31, 2023 (Unaudited) Assets Current assets Cash and cash equivalents $ 26,964 $ 33,107 Restricted cash 2,500 4,650 Accounts receivable, net of allowances of $ 8,398 and $ 7,130 , respectively 125,617 128,098 Inventories 219,076 222,166 Prepaid expenses and other current assets 24,821 32,422 Total current assets 398,978 420,443 Property, plant, and equipment, net 158,132 159,060 Intangible assets, net 112,761 117,490 Goodwill 194,934 194,934 Other long-term assets 41,245 33,388 Total assets $ 906,050 $ 925,315 Liabilities and shareholders' equity Current liabilities Accounts payable $ 57,147 $ 58,357 Current portion of long-term debt 3,125 1,250 Current portion of finance lease liability 724 708 Other current liabilities 89,625 104,908 Total current liabilities 150,621 165,223 Long-term debt 115,071 93,107 Long-term portion of finance lease liability 18,345 18,532 Other long-term liabilities 51,698 49,723 Total liabilities 335,735 326,585 Contingencies (Note 8) Shareholders' equity Common shares $ 0.10 par value; 100,000 shares authorized; 37,410 and 37,165 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 3,741 3,717 Additional paid-in capital 753,398 746,450 Accumulated deficit ( 186,164 ) ( 150,144 ) Accumulated other comprehensive loss ( 660 ) ( 1,293 ) Total shareholders' equity 570,315 598,730 Total liabilities and shareholders' equity $ 906,050 $ 925,315 The accompanying notes form an integral part of these condensed consolidated financial statements 4 ORTHOFIX MEDICAL INC. C ondensed Consolidated Statements of Operations and

View Full Filing

View this 10-Q filing on SEC EDGAR